Calm Before The Storm – But Some Medtechs Already Reflect The Ravages Of COVID-19

2019 saw fewer revenue-boosting major acquisitions by top-tier medtechs. Companies that reported after the calendar year-end were the first to see the consequences of the pandemic on their annual figures.

Red umbrella
• Source: Shutterstock

Our sales ranking of the top 100 publicly traded medtech manufacturers is COVID-19-affected for a relatively sizeable proportion of companies ̶ those whose reporting periods closed during 2020. The effect of the pandemic on their sales was often significant and gave a foretaste of what the rest of the industry will experience when filing calendar year 2020 accounts.

The first implications of the pandemic became apparent for health care provider systems in countries beyond China at the end...

In Vivo Podcast

Candid conversations with C-suite leaders.

Keep up with strategy, innovation and evolving trends across life science industries.

More from Business Strategy

More from In Vivo